Table 3 Clinical individual patient and immunohistochemical melanoma metastases characterization

High clinical benefit

 MEL1

PAT1

PR

46

Before

Ipi

B

Yes

Yes

No

LN

Yes

 MEL2

PAT2

PR

37+

This sample is a regression lesion

After

TriMixIpi

E

Yes

Yes

Yes

Sc nodule

Yes

 MEL3

PAT3

CR

39+

Before

TriMixIpi

C

Yes

Yes

Yes

LN

Yes

 MEL4

C

Yes

Yes

Yes

LN

No

 MEL5

PAT4

CR

43+

Before

TriMixIpi

C

Yes

Yes

Yes

LN

Yes

 MEL6

PAT5

CR

29+

Before

TriMixIpi

B

No

Yes

Yes

Skin MTS

Yes

 MEL7

C

No

Yes

Yes

LN

No

No clinical benefit

 MEL14

PAT12

PD

14

After

TriMixIpi

C

No

Yes

Yes

Small intestine

Yes

 MEL15

PAT13

PD

3

Before

TriMixIpi

B

Yes

Yes

Yes

LN

Yes

 MEL16

PAT14

PD

13

After

TriMixIpi

C

Yes

Yes

Yes

LN

Yes

 MEL17

PAT15

PD

14

After

TriMixIpi

A/B

No

Yes

Yes

Brain

Yes

 MEL18

PAT16

PD

8

First line was Ipi but MTS was removed after receiving also TriMixIpi

After

Ipi

C

No

Yes

Yes

Liver

Yes

 MEL19

PAT17

PD

6

Before

Ipi

NE

NE

Yes

NE

Adrenal gland

Yes

 MEL20

PAT18

PD

9

Before

TriMixIpi

B

No

Yes

No

Sc nodule

Yes

 MEL21

PAT19

PD

16

Before

Ipi

Heterogenous A and C

No

Yes

Yes

Small intestine

No

 MEL22

PAT20

PD

10

Before

Ipi

Heterogenous E and C

No

Yes

Yes

Lung

No

 MEL23

PAT21

PD

26

First line was Ipi but MTS was removed after receiving Ipi, TriMixIpi and Ipi reinduction

After

Ipi

D

No

Yes

Yes

Sc nodule

No

 MEL24

PAT22

PD

10

After

TriMixIpi

E but weak infiltration

No

Yes

Yes

Sc nodule

No

 MEL25

PAT23

PD

10

Before

TriMixIpi

NE

NE

NE

NE

LN

No

 MEL26

PAT24

PD

35

Experienced DC vaccination, Ipi, Ipi reinduction, DC vaccination combined with Ipi, and TIL therapy

After

Ipi

C

Yes

Yes

Yes

Sc nodule

No